Evidence map›Paper›PMID 30426396›Full record

ArticleHepatology international2018

Risks of hepatocellular carcinoma and cirrhosis-associated complications in patients with rheumatoid arthritis: a 10-year population-based cohort study in Taiwan.

Ching-Sheng Hsu, Hui-Chu Lang, Kuang-Yung Huang, You-Chen Chao, Chien-Lin Chen

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Hepatology international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02880306 (Hepatocellular Carcinoma and Rheumatoid Arthritis), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02880306 completednot on this map

Hepatocellular Carcinoma and Rheumatoid Arthritis

TypeobservationalSponsorTaipei Tzu Chi Hospital, Buddhist Tzu Chi Medical FoundationRan2014 to 2016Enrolled741,379ConditionsCarcinoma, HepatocellularArmsRA
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 17 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Ching-Sheng HsuLiver Diseases Research Center, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No. 289 Jianguo Rd, Xindian Dist, New Taipei City, 23142, Taiwan, ROC. hsu.chingsheng@gmail.com.ORCID http://orcid.org/0000-0002-9342-0826
Hui-Chu LangInstitute of Hospital and Health Care Administration, National Yang-Ming University, Taipei, Taiwan, ROC.
Kuang-Yung HuangSchool of Medicine, Tzu Chi University, Hualien, Taiwan, ROC.
You-Chen ChaoLiver Diseases Research Center, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No. 289 Jianguo Rd, Xindian Dist, New Taipei City, 23142, Taiwan, ROC.
Chien-Lin ChenSchool of Medicine, Tzu Chi University, Hualien, Taiwan, ROC. harry.clchen@msa.hinet.net.
Tzu Chi University · TWNational Chung Cheng University · TWNational Yang Ming Chiao Tung University · TW

Funding

Buddhist Tzu Chi Medical Foundation TCMMP104-02-01Taipei Tzu Chi Hospital TCMMP104-02-02Taipei Tzu Chi Hospital TCRD-TPE-104-31Taipei Tzu Chi Hospital TCRD-TPE-106-RT-8
6 · The paper itself

Abstract

background/purposeAlthough rheumatoid arthritis (RA) has been linked to several important malignancies, data for the risks of hepatocellular carcinoma (HCC) in patients with RA are scarce. We aimed to examine the risk of HCC and cirrhosis-associated complications and the use of biologics in a national representative RA sample in Taiwan.

methodsAll study subjects aged ≥ 18 years in the Taiwan National Health Insurance program between January 1, 2000, and December 31, 2009 were enrolled. We matched RA and non-RA subjects by propensity scores in a 1:1 ratio. Our primary outcome was a diagnosis of HCC and cirrhosis-associated complications during a 10-year follow-up period. The risk of outcomes was represented as a hazard ratio (HR) calculated in Cox proportional hazard regression models.

results24,245 RA and 24,245 non-RA subjects were included in the primary outcome analysis. Mean overall person-years (PY) of follow-up were 116,608 PY for the RA cohort, and 234,280 PY for the non-RA cohort. The overall incidence of HCC and cirrhosis-associated complications was lower in the RA cohort than in the non-RA cohort (0.66% vs. 1.41% HCC events and 1.45% vs. 1.95% cirrhosis-associated complications events during 10-year follow-up). The HRs adjusted for age, sex, the frequency of medical visits, and CCI were 0.57 (0.46-0.71) for HCC and 0.67 (0.59-0.76) for HCC and cirrhosis-associated complications. Although immunomodulatory agents may alter the risk of malignancy, use of biologics did not increase HCC risk in RA patients.

conclusionsRA is associated with a reduced risk of developing HCC and cirrhosis-associated complications. CLINICAL

trial registrationClinicalTrials.gov identifier NCT02880306.

Indexed as

AdolescentAdultAgedArthritis, RheumatoidAscitesBiological ProductsCarcinoma, HepatocellularEsophageal and Gastric VaricesFemaleFollow-Up StudiesHepatic EncephalopathyHepatitis BHepatitis CHumansImmunologic FactorsIncidenceBiological ProductsImmunologic FactorsCirrhosis-associated complicationsInflammationOutcomes researchPatient perspectiveRheumatoid arthritis

Identifiers

PMID30426396
OpenAlexW2901493770

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.